|
| Study | Type | Drug/comp. | Number of pts/Age | Outcome | Results |
|
| TOP-CAT | Outcome | Spironolactone versus placebo | 3445/69 | Primary outcome: CV death/HF hospitalization/aborted cardiac arrest | In follow-up 3.3 years 18 versus 20 () |
|
| Aldo-DHF | PoC | Spironolactone versus placebo | 422/67 | Coprimary outcomes:
(i) Diastolic dysfunction (E/E′)
(ii) Exercise capacity/peak VO2 | In 12-month follow-up
(i) 12.1 versus 13.6 ()
(ii) 16.8 versus 16.9 () |
|
| RELAX | PoC | Sildenafil versus placebo | 216/69 | Primary outcome:
exercise capacity/peak VO2
Secondary outcome:
(i) 6 min walk test
(ii) Clinical outcome | In 24-week follow-up
(i) −0.2 versus −0.2 ()
(ii) 5.0 versus 15 m ()
(iii) 94 versus 95 () |
|
| PARAMOUNT | PoC | LCZ 696 angiotensin rec. + Neprilysin inhib. versus valsartan | 266/71 | Change NT-proBNP
Side effects | Ratio LCZ696/valsartan 0.77 ()
22 patients (15%) on LCZ696 versus 30 (20%) on valsartan |
|
| DHART | PoC | Anakinra versus placebo | 12/62 | Exercise capacity/peak VO2 | +1.2 mL/kg/min (+8%, ) |
|
| RALI-DHF | PoC | Ranolazine (iv 24 h infusion followed by 13 days of oral treatment)
versus placebo | 20/73 | Changes in hemodynamic parameters
Changes in echocardiography, PeakVO2, and NT-proBNP parameters | LVEDP (mmHg) 23 versus 19 (); PCWP 18 versus 12 ()
No changes () |
|
| Kosmala | PoC | Ivabradine versus placebo | 61/67 | Exercise capacity (METS)
Peak VO2 | +1.5 versus +0.4 ()
+3.0 versus +0.4 () |
|
| PARAGON-HF | Outcome | LCZ956 versus valsartan | | CV death and HF Hospitalization | Ongoing |
|
| SOCRATES-PRESERVED | PoC | Vericiguat (guanylate cyclase stimulator) | | Change in NT-proBNP | Ongoing |
|
| EDIFY | Outcome | Ivabradine versus placebo | 400 | Diastolic dysfunction (E/E′, exercise capacity, NT-proBNP) | Ongoing |
|
